Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 8.3% year on year to $5.89 billion. Its non-GAAP profit of $3.96 per share was 1.2% above analysts’ consensus estimates. Is now the time to buy BDX? Find out in our full research report (it’s free for active Edge members). BD (BDX) Q3 CY2025 Highlights: Revenue: $5.89 billion vs analyst estimates of $5.91 billion (8.3% year-on-year growth, in line) Adjusted EPS: $3.96 v ...

Becton, Dickinson and Company (NYSE:BDX) Q4 2025 Earnings Call November 06, 2025 08:00 AM ET Speaker1Hello and welcome to BD's fourth quarter and full year fiscal 2025 earnings call. At the request of BD, today's call is being recorded and will be available for replay on BD's investor relations website, investors.bd.com, or by phone at 800-839-2383 for domestic calls and area code +1-402-220-7202 for international calls. For today's call, all parties have been placed in a listen-only mode until the question ...